Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Fineline Cube Apr 20, 2026
Company Deals

Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium

Fineline Cube Apr 20, 2026
Company Deals

SenseTime Raises $73.3 Million in Series A Financing for AI Healthcare Platform – Medical Agentic OS and World Model Capabilities Attract Raffles Healthcare, Lion Partners

Fineline Cube Apr 20, 2026
Company Deals

Mabwell Bioscience Raises $185 Million in Hong Kong IPO After Two Previous Failed Attempts – Oncology and Age-Related Disease Developer Secures HK$1.45 Billion Valuation

Fineline Cube Apr 20, 2026
Company Deals

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio

Fineline Cube Apr 20, 2026
Policy / Regulatory

China’s NMPA Proposes New Quality Management Standards for Drug Retail Chains – Mandating Unified Systems Across Headquarters, Distribution Centers, and Stores

Fineline Cube Apr 20, 2026
Company Drug

LEO Pharma Secures NMPA Approval for Enstilar Foam in China – First and Only Calcipotriol/Betamethasone Foam Formulation for Plaque Psoriasis Demonstrates Superior Efficacy vs. Ointment

Fineline Cube Apr 20, 2026
Company Drug

Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication

Fineline Cube Apr 20, 2026
Company Medical Device

Peijia Medical Completes First Two Implants of Trilogy THV System in Taiwan

Fineline Cube Mar 6, 2025

China’s Peijia Medical Ltd (HKG: 9996) announced the completion of the first two implant surgeries...

Company Medical Device

Huadong Medicine’s V30 Optical Radiofrequency Device Receives NMPA Review Approval

Fineline Cube Mar 6, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that the National Medical Products Administration (NMPA)...

Company Deals

Jiangsu Nhwa Pharmaceutical Invests in NeuroThree to Develop CNS Therapies

Fineline Cube Mar 6, 2025

China-based Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262) announced plans to subscribe to Hong Kong-headquartered...

Company

Bayer Posts Steady Q4 Growth, Pharmaceutical Sales Lead the Way

Fineline Cube Mar 6, 2025

German giant Bayer (ETR: BAYN) has released its Q4 2024 financial results, reporting a 0.7%...

Company

NovoCare Pharmacy Offers Reduced-Cost Wegovy for Cash-Paying Patients

Fineline Cube Mar 6, 2025

Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced the launch of NovoCare Pharmacy, a direct-to-patient...

Company Drug

Antengene’s Xpovio Receives Marketing Approval in Indonesia

Fineline Cube Mar 6, 2025

China-based biopharma Antengene Corp., Ltd (HKG: 6996) announced receiving marketing approval in Indonesia for its...

Company Medical Device

Sino Medical Sciences’ HT Supreme Stent System Gains Vietnamese Marketing Approval

Fineline Cube Mar 6, 2025

China-based Sino Medical Sciences Technology Inc., (SHA: 688108) announced that it has received marketing approval...

Company Deals

Yifan Pharma Secures Rights to Bayer’s Stivarga and Nexavar in China

Fineline Cube Mar 6, 2025

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced a commercialization agreement with Bayer (ETR: BAYN),...

Policy / Regulatory

Major Policy Directions in China’s Healthcare Arena: A Comprehensive Breakdown

Fineline Cube Mar 6, 2025

In a momentous address at the Third Session of the 14th National People’s Congress on...

Company Drug

RongCan Biotech’s mRNA HPV Vaccine Receives FDA Clinical Approval

Fineline Cube Mar 6, 2025

China-based mRNA specialist RongCan (Shanghai) Biotech Co., Ltd announced that it has received clinical approval...

Company Deals

Insilico Medicine and Tenacia Partner on AI-Driven CNS Therapies

Fineline Cube Mar 6, 2025

China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has formed a partnership with compatriot firm...

Company Deals

Lexenpharm and Sun-Novo Partner on Long-Acting Asthma and COPD Drugs

Fineline Cube Mar 6, 2025

China-based Lexenpharm has formed a partnership with compatriot firm Beijing Sun-Novo Pharmaceutical Research Co., Ltd...

Company Deals

Baheal Pharmaceutical Gains Exclusive Rights to Roche’s MabThera in China

Fineline Cube Mar 6, 2025

China-based health services and distribution giant Baheal Pharmaceutical Group (SHE: 301015) last month reached an...

Company Drug

Zhejiang Huahai’s HB0034 Meets Primary Endpoint in GPP Study

Fineline Cube Mar 6, 2025

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that its multi-center, double-blinded, randomized, placebo-parallel...

Company Deals

CStone Pharmaceuticals and SteinCares Ink Licensing Deal for PD-L1 Inhibitor in Latin America

Fineline Cube Mar 6, 2025

China-based CStone Pharmaceuticals (HKG: 2616) and Costa Rica-based drug maker and distributor SteinCares have entered...

Company Drug

Fosun Pharma’s 24-Valent Pneumococcal Vaccine Receives NMPA Approval for Phase I Trial

Fineline Cube Mar 6, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd’s (SHA: 600196, HKG: 2196) subsidiary Fosun Adgenvax (Chengdu)...

Company Deals

Bio-Thera Solutions Inks Licensing Deal with World Medicine for BAT2206

Fineline Cube Mar 5, 2025

China-based Bio-Thera Solutions (SHA: 688177) has entered into a licensing agreement with World Medicine, granting...

Company Deals

Hainan Poly Pharm’s US Partner Slate Run Pharmaceuticals Collaborates with Premier on Contrast Agents

Fineline Cube Mar 5, 2025

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) announced a significant partnership between its US...

Company Deals

Gensaic and Novo Nordisk Team Up to Develop Cardiometabolic Therapies

Fineline Cube Mar 5, 2025

US-based AI-powered biotech Gensaic, Inc. announced the signing of a licensing and discovery cooperation agreement...

Company

MSD China Reorganizes to Boost Mature Product Lines

Fineline Cube Mar 5, 2025

Anna Van Acker, Senior Vice-President of Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) and...

Posts pagination

1 … 189 190 191 … 654

Recent updates

  • LEO Pharma Secures NMPA Approval for Enstilar Foam in China – First and Only Calcipotriol/Betamethasone Foam Formulation for Plaque Psoriasis Demonstrates Superior Efficacy vs. Ointment
  • Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication
  • UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection
  • Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 – 47.1% ORR and 14.0-Month PFS in Solid Tumors
  • Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

LEO Pharma Secures NMPA Approval for Enstilar Foam in China – First and Only Calcipotriol/Betamethasone Foam Formulation for Plaque Psoriasis Demonstrates Superior Efficacy vs. Ointment

Company Drug

Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication

Company Deals

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Company Drug

Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 – 47.1% ORR and 14.0-Month PFS in Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.